Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginReturn on AssetsReturn on Capital EmployedReturn on Sales

ProQR Therapeutics N.V (PRQR) FCF Margin: 2021-2025

Historic FCF Margin for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to -424.53%.

  • ProQR Therapeutics N.V's FCF Margin fell 27733.00% to -424.53% in Q3 2025 from the same period last year, while for Sep 2025 it was -332.50%, marking a year-over-year decrease of 15129.00%. This contributed to the annual value of -214.17% for FY2024, which is 52392.00% down from last year.
  • Latest data reveals that ProQR Therapeutics N.V reported FCF Margin of -424.53% as of Q3 2025, which was down 42.13% from -298.69% recorded in Q2 2025.
  • Over the past 5 years, ProQR Therapeutics N.V's FCF Margin peaked at 3,711.62% during Q2 2023, and registered a low of -8,341.13% during Q1 2021.
  • Over the past 3 years, ProQR Therapeutics N.V's median FCF Margin value was -288.95% (recorded in 2024), while the average stood at 106.30%.
  • Examining YoY changes over the last 5 years, ProQR Therapeutics N.V's FCF Margin showed a top increase of 652,990bps in 2022 and a maximum decrease of 406,049bps in 2022.
  • ProQR Therapeutics N.V's FCF Margin (Quarterly) stood at 1,583.68% in 2021, then plummeted by 406,049bps to -2,476.81% in 2022, then skyrocketed by 231,475bps to -162.06% in 2023, then crashed by 11,716bps to -279.22% in 2024, then tumbled by 27,733bps to -424.53% in 2025.
  • Its last three reported values are -424.53% in Q3 2025, -298.69% for Q2 2025, and -349.59% during Q1 2025.